Emergence of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infection in Queensland, Australia  by Munckhof, Wendy J. et al.
Original Report 
Emergence of community-acquired methicillin-resistant 
Staphylococcus aureus (MRSA) infection in Queensland, 
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and Graeme R. Nimmo(2) 
Objectives: To investigate the incidence and epidemiology of non-multiresistant methicillin-resistant Staphylococcus 
aweus (nmMRSA) infection in south-east Queensland, Australia. 
Study design: A retrospective survey was done of hospital records of all patients who had non-multiresistant MRSA 
isolated at Ipswich Hospital (a 250-bed general hospital, 40 km south-west of Brisbane, Queensland, Australia) 
between March 2000 and June 2001. Laboratory typing of these isolates was done with antibiogram, pulsed:field gel 
electrophoresis, bacteriophage typing and coagulase gene typing. 
Results: There were 44 infections caused by nmMRSA. Seventeen infections (39%) occurred in patients from the 
south-west Pacific Islands (predominantly Samoa, Tonga and New Zealand). Laboratory typing showed that the 
isolates in Pacific Islanders were Pacific Island strains, and 16/17 of these infections were community acquired. 
Twenty-three infections (52%) occurred in Caucasians. Eleven of the isolates from Caucasians (48%) were a new 
predominantly community-acquired strain that we have termed the ‘R’ pulsotype, nine (39%) were Pacific Island 
strains, and three (13%) were health care institution-associated strains. Four infections occurred in patients who were 
not Caucasians or Pacific Islanders. Overall, 34 of all 44 infections (77%) were community acquired. 
Conclusions: Non-multiresistant MRSA infection, relatively frequently observed in Pacific Islanders in south-east 
Queensland, is now a risk for Caucasians as well, and is usually community acquired. Clinicians should consider 
taking microbiological specimens for culture and antimicrobial susceptibility testing in patients with suspected 
staphylococcal infections who are not responding to empirical therapy with B-lactam antibiotics. 
Int J Infect Dis 2003; 7:259-267 
INTRODUCTION 
Methicillin-resistant Staphylococcus aureus (MRSA) 
has been recognized since the 1970s as an important 
cause of nosocomial infection in Australian hospita1s.r In 
the last 10 years, community-acquired strains of MRSA 
have arisen in many countries, including the USAF4 
Canada,s and New Zealand.6.7 In the late 1980s the first 
Australian cases of community-acquired MRSA 
infection were reported in the remote Kimberley region 
of Western Australia.8%9 These strains were dubbed ‘WA 
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MRSA’, and colonization rates in remote Aboriginal 
communities are high.lO,ll All strains of MRSA are resis- 
tant to all l3-lactam antibiotics, and nosocomial strains of 
MRSA in most countries, including Australia, are 
usually resistant in vitro to many non-p-lactam anti- 
biotics.1,4,12 However, community-acquired MRSA 
strains in most countries, including Australia, are 
typically non-multiresistant.1%3m5 
In the last 5 years, a new variety of non- 
multiresistant MRSA (nmMRSA) has emerged in 
Australia, particularly along the eastern seaboard.13-l5 
Infections are usually community acquired, and occur 
predominantly in people from the south-western Pacific 
Islands, such as Samoa and Tonga. These strains have 
Western Samoan phage patterns (WSPP) on bacterio- 
phage typing, and typing by pulsed-field gel electro- 
phoresis (PFGE) shows a typical ‘A’ pulsotype.14 Similar 
strains have caused community-acquired infections in 
Pacific Islanders in New Zealand.6%7 
This study was performed because the incidence 
of infections due to community-acquired nmMRSA 
appeared to be increasing at Ipswich Hospital, partic- 
ularly in Caucasians. If the incidence of this infection 
were high enough, it would alter the choice of empirical 
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therapy in severe community-acquired staphylococcal 
sepsis, for which B-lactam antibiotics represent the usual 
current therapy of choice. Therefore, the aim of the 
current study was to determine the relative incidence of 
nmMRSA in Polynesian, Caucasian and other ethnic 
groups, and to determine if the infections were likely to 
be nosocomially, or community acquired. We also typed 
the strains of nmMRSA to determine if they were clonal 
and/or related to previously described strains of 
nmMRSA. 
METHODS 
Patients and setting 
Ipswich Hospital is a general hospital of 250 beds, 40 km 
south-west of Brisbane in south-east Queensland, 
Australia. It services a population of approximately 
125 000 people, 3% of whom of were born in the south- 
western Pacific Islands (predominantly Tonga, Samoa, 
Fiji, and the Cook Islands) or New Zealand.16 
We performed a retrospective medical record 
review of all patients who had nmMRSA isolated from 
clinical specimens sent to the Ipswich Hospital micro- 
biology laboratory during a 16-month period between 
1 March 2000 and 30 June 2001. MRSA isolates were 
classified as non-multiresistant if they tested resistant to 
two or fewer classes of non-p-lactam antibiotics 
(gentamicin, erythromycin, clindamycin, tetracycline, 
cotrimoxazole, ciprofloxacin, rifampicin, fusidic acid, 
vancomycin) in addition to p-1actams.l 
Data collection 
The medical records of all patients who had nmMRSA 
isolated from clinical specimens during the study period 
were available and were reviewed. The following 
characteristics were identified in the medical record 
review: demographics, including place of birth and 
ethnicity, date of treatment, coexisting morbidities, risk 
factors for acquisition of MRSA in the previous 12 
months, clinical manifestations of infection, and 
outcome (duration of hospital admission, need for 
surgery, whether discharged to usual residence, whether 
outcome was fatal, treatment with antibiotics with and 
without in vitro activity against MRSA). 
Classification of infections as community acquired 
or nosocomial (hospital, hospital-based unit, nursing 
home or other long-term care institution) was in 
accordance with Centers for Disease Control 
definitions.17 Infections were classified as: 
1. Community-acquired if S. u.UreUS was isolated from 
a specimen taken within 48 h of hospital present- 
ation, and 
2. With no risk factors if the patient had not attended 
a hospital or hospital-based unit, or resided in a 
nursing home or other long-term care institution, 
within the 12 months before presentation, and did 
not have a predisposing chronic disease (including 
diabetes, liver disease, renal failure, malignancy, HIV 
infection, intravenous drug use or corticosteroid 
therapy). 
Laboratory analysis and typing of isolates 
S. aureus was identified by the Slidex Staph-Kit latex 
agglutination test (bioMerieux, Lyon, France) and by 
detection of the yluc gene, and oxacillin (methicillin) 
resistance was confirmed by detection of the mecA gene. 
The multiplex PCR procedure used was based on a 
modification of the method of Unal et a&l* the mecA 
primers were as described by Murakami and Minamide,19 
and the nut primers were as described by Brakstad et 
a1.20 The 25-FL reaction mixture consisted of 10 FL of 
lysate, 100 ~.LM (each) deoxynucleoside triphosphate, 
0.2 ~J,M (each) primer, and 0.5 U of AmpliTaq DNA 
polymerase (Perkin Elmer, Roche Molecular Systems 
Inc., NJ, USA) in 10X PCR buffer (1 x is 10 mM Tris- 
HCl (pH 8.3) 50 mM KCl, 1.5 mM MgC12,0.001% (w/v) 
gelatin). DNA amplification consisted of an initial cycle 
of 94°C for 5 min, 55°C for 30 s, and 72°C for 2 min, 
followed by 29 cycles of 94°C for 30 s, 55°C for 30 s, and 
72°C for 2 min. PCR products were visualized on 2% 
agarose gels stained with ethidium bromide. 
Antimicrobial susceptibility testing was performed on 
the isolates using the VITEK GPS-IX card (bioMerieux- 
Vitek, Hazelwood, MO, USA), and was confirmed using 
standard National Committee for Clinical Laboratory 
Standards disk methodology.21,22 
Typing was performed on isolates from all patients 
of non-Pacific Island ethnicity. Seven of the 17 patients 
of Pacific Island ethnicity had isolates typed. These 
seven isolates from Pacific Islanders were taken 
randomly throughout the study, and yielded identical 
typing results to those previously published for this 
ethnic group.14 For this reason, and because typing is 
very expensive and time-consuming, not every patient in 
this ethnic group had an isolate tested. Isolates were 
typed with the following four methods: antibiotyping 
using the antimicrobial susceptibility testing pattern, 
PFGE, bacteriophage typing, and coagulase gene typing 
by restriction analysis of PCR products. 
Fingerprinting by pulsed-jield gel electrophoresis 
PFGE of chromosomal DNA was performed using the 
enzyme SmaI. DNA was separated on a GenePath 
system (Bio-Rad, Hercules, CA, USA), using the 
GenePath group 1 reagent kit (Bio-Rad) with initial pulse 
times of 5.3 and 34.9 s at the end of the 20-h run. Gels 
were stained with ethidium bromide and photographed 
under UV illumination. The patterns were confirmed 
visually using the criteria of Tenover et a1,23 and were 
analyzed with GelCompar software (Applied Maths, 
Kortrijk, Belgium). Results were analyzed using the 
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unweighted pair group method for arithmetic averages 
and the Dice coefficient with 1.2% band tolerance.24 
Bacteriophage typing 
Phage typing was performed using the method of Blair 
and Williams.25 The following phage-typing sets were 
used: the Basic International Set of Typing Phages (23 
phages), the International Set of Experimental Phages 
for MRSA (10 phages)F6 and the Australian Set of 
Experimental Phages for MRSA (nine phages).27 All 
phages were used at 100x routine test dilution. 
Coagulase gene typing by restriction analysis 
of PCR products 
Molecular typing on the basis of coagulase gene poly- 
morphisms was performed by a modification of the 
method of Goh et a1.28 
Relative incidence of methicillin and gentamicin 
resistance in Staphylococcus aureus 
We used the laboratory information system database to 
locate all patient isolates of S. aweus at the Ipswich 
Hospital microbiology laboratory between 1 March 
2000 and 30 June 2001. Because in vitro resistance to 
gentamicin is a good surrogate marker of nosocomial 
acquisition of MRSA, and conversely community- 
acquired strains of MRSA are usually gentamicin 
susceptible in vitro,1,13-15,29 we used gentamicin suscepti- 
bility as a surrogate marker of community acquisition of 
strains. 
RESULTS 
Forty-four cases of infection caused by nmMRSA were 
identified from clinical specimens sent to the Ipswich 
Hospital microbiology laboratory. 
Patient characteristics and clinical manifestations of 
infection 
The medical records of all 44 patients were reviewed. 
Patient characteristics are shown in Table 1. Most 
patients were born in Australia, New Zealand or the 
Pacific Islands. Thirty-two of the 44 patients (73 %) were 
male, and this sex bias was particularly noted in the 
Pacific Islander group. Of note is the youth of many 
patients, with 41% of Pacific Islanders and 31% of 
Caucasians aged less than 20 years. Seventy percent of 
all patients presented with superficial abscesses or boils, 
and there were four serious life-threatening infections. 
Thirty-four of the 44 patients were hospitalized, with 
nine patients being hospitalized for more than 1 week. 
Figure 1 shows the incidence of infections for the 
various ethnic groups over the study period. 
Antibiotic resistance 
Forty-one of the 44 strains of nmMRSA were suscept- 
ible in vitro to all of the non-B-lactam antibiotics tested. 
In vitro non+-lactam antibiotic resistance was found in 
three strains that were resistant to erythromycin, and 
one of these strains was also resistant to clindamycin. We 
have previously described erythromycin and inducible 
clindamycin resistance in two Pacific Islanders from 
Table 1. Characteristics of 44 patients infected with non-multiresistant MRSA at lpswich Hospital, by ethnic group 
Caucasian 
South-west 
Pacific IslandeP Other ethnicitv Total 
Demographic characteristics 
Number of cases of infection 
Male 
Median age in years (range) 
Place of birth 
Australia 
New Zealand 
South-west Pacific Islands3 
Other country 
Nature of infection 
Boil/superficial abscess 
Cellulitis 
Surgical wound infection 
Septic arthritis 
Diabetic foot osteomyelitis 
Septicemia 
Septicemia and osteomyelitis 
Pulsotype by pulsed-field gel electrophoresis 
A pulsotype (Pacific Island type) 
R pulsotype (new strain) 
Other strains 
23 
15123 (65%) 
31.5 
20 5 
2 4 
0 8 
1 0 
14 
5 
1 
0 
1 
1 
1 
9 7b 2 18 
11 0 2 13 
3 0 0 3 
::/17 (88%) 2: (50%) 
34.5 23.3 
14 
2 
0 
1 
0 
0 
0 
44 
32144 (73%) 
33 
28 
6 
8 
2 
31 
8 
1 
1 
1 
1 
1 
5outh-west Pacific Islander denotes person of south-west Pacific Island ethnicity, predominantly Tongan or Samoan 
bTyping by PFGE was performed on seven of the 17 patients of Pacific Island ethnicity. 
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18 
I 
Total 
61 Caucasians 
Pacific Islander* 
l3.l Other ethnic group 
I 
March to June 2000 July to October 2000 November to February 2001 March to June 2001 
Time 
*Pacific Islander denotes person of south-western Pacific Island ethnicity, predominantly Tonga or Western Samoa. 
Figure 1. Frequency of cases of non-multiresistant MRSA infection at lpswich Hospital, by ethnic group. 
Ipswich with community-acquired MRSA infection30 without risk factors for acquisition of MRSA, and the 
but there were no further isolates of this strain. other three strains were hospital associated. 
Typing results and risk factors for acquisition of 
MRSA 
GROUP 2: NEW STRAIN ‘R PULSOTYPE’ 
Pacific Islanders 
There were 17 isolates of nmMRSA obtained from 
Pacific Islanders, and all were resistant to p-lactam 
antibiotics only. All seven isolates that were typed were 
pulsotype A pattern on PFGE (Figure 2), typical of the 
Pacific Island strain.14 Sixteen of the 17 Pacific Islanders 
had community-acquired infections. All three patients 
with community-acquired infections who had risk 
factors for acquisition of MRSA had diabetes mellitus. 
Caucasians 
There were 23 isolates of nmMRSA in Caucasians 
(Table l), which fell into three distinct groups on typing 
by PFGE: 
Typing results for 11 isolates from Caucasians showed a 
clonal pattern on PFGE, which we have termed the ‘R’ 
pulsotypezl (Figure 2). This PFGE pattern is new to 
Queensland,31 and was not seen in a 1997-98 Brisbane 
study of MRSA.14 These isolates were also non-typable 
on phage typing. All isolates were resistant to p-lactam 
antibiotics only, with the exception of one early 
erythromycin- and clindamycin-resistant isolate. Seven 
strains were community acquired in patients with no risk 
factors for acquisition of MRSA, one community- 
acquired strain occurred in an intravenous drug user, 
and the other three strains were hospital associated. All 
three hospital-acquired infections occurred within the 
same month in patients admitted to the surgical ward at 
the hospital. The index case of this cluster was a long- 
term psychiatric hospital inmate. All R pulsotype strains 
were isolated in the last 9 months of the 16-month study. 
GROUP 1: ‘PACIFIC ISLAND PATTERN’ 
Nine strains in Caucasians were of the pulsotype A 
Pacific Island pattern on PFGE (Figure 2). These 
isolates were resistant only to p-lactam antibiotics. Six of 
these strains were community acquired in patients 
GROUP 3: MIXED HEALTH CARE INSTITUTION- 
ASSOCIATED STRAINS 
The last three isolates in Caucasians had three differ- 
ent patterns on PFGE and had additional in vitro 
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Figure 2. Pulsed-field gel electrophoresis (PFGE) of strains of MRSA isolated in south-east Queensland, Australia. Lanes 1, 7 and 15: 
size markers. Lanes 2 and 3: A pulsotype community-acquired strains isolated from Pacific Islanders at Princess Alexandra Hospital, 
Brisbane, Queensland, Australia. Lane 4: nosocomially acquired strain from a Caucasian isolated at Princess Alexandra Hospital, 
Brisbane. Lanes 5, 6, 11 and 12: A pulsotype community-acquired lpswich strains isolated from Pacific Islanders. Lanes 8 and 9: A 
pulsotype community-acquired lpswich strains isolated from Caucasians. Lane 10: new R pulsotype community-acquired lpswich 
strains isolated from a Caucasian. Lanes 13 and 14: nosocomially acquired lpswich strains isolated in Caucasians. 
non-p-lactam antibiotic resistances (erythromycin, 
clindamycin). All three strains were hospital associated. 
Other ethnic groups 
There were two isolates of the new ‘R’ pulsotype 
obtained from an Aboriginal and a Torres Strait 
Islander. These infections were community acquired in 
patients with no risk factors for acquisition of MRSA 
and occurred towards the end of the study, after the first 
isolates of this strain in Caucasians. There were also two 
community-acquired infections in Africans, one of 
whom had diabetes mellitus, which were of pulsotype A 
(Pacific Island pattern) on typing with PFGE. 
Outcomes 
There were no deaths, and all patients were discharged 
to their usual residences. Thirty of 44 patients 
underwent surgical treatment, with 25 of the 31 
patients with superficial abscesses or boils being 
treated with incision and drainage. All 44 patients were 
treated with antibiotics. Twenty-five of the 44 patients 
were treated only with p-lactam antibiotics, which have 
no activity against MRSA (penicillin, flucloxacillin, 
dicloxacillin, ampicillin, ampicillin-clavulanic acid, 
cephalexin, and ceftriaxone). The other 19 patients 
mostly received a p-lactam antibiotic until MRSA was 
cultured, and were then changed to antibiotics with in 
vitro activity against MRSA. These antibiotics included 
intravenous vancomycin (seven patients), intravenous 
vancomycin followed by oral clindamycin (two 
patients), intravenous vancomycin followed by oral 
clindamycin followed by oral rifampicin and fusidic 
acid (one patient), intravenous vancomycin with 
concurrent oral rifampicin (one patient), intravenous 
vancomycin followed by oral erythromycin (one 
patient), oral erythromycin (five patients), and oral 
clindamycin (two patients). 
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Relative incidence of methicillin and gentamicin 
resistance in Staphylococcus aureus 
By using the laboratory information system database, 
we located all patient isolates of S. aweus at the Ipswich 
Hospital microbiology laboratory between 1 March 
2000 and 30 June 2001 (Figure 3). We noted that the total 
monthly isolation rate of S. aureus did not change 
significantly, and that methicillin-susceptible strains 
comprised between 73 % and 92% of all S. aureus strains 
isolated, depending on the month. Gentamicin-resistant 
MRSA, predominantly nosocomially acquired in 
patients transferred to Ipswich Hospital from Brisbane 
tertiary hospitals, comprised 3-19% of all S. aureus 
strains isolated. Gentamicin-susceptible strains of 
MRSA, a surrogate marker of community acquisition of 
MRSA, comprised 4-16% of all isolates of S. aureus, 
with some variability from month to month, but 
concluding at a rate of 10% of S. aureus at the end of the 
study. 
DISCUSSION 
MRSA was traditionally considered to be a nosocomial 
pathogen until the emergence of community-acquired 
MRSA in Australia, initially in the 1980s from Western 
Australia.l.s The classification of acquisition status in the 
study of community-acquired MRSA infection is 
controversial. Contact with a health care institution in 
the 12 months prior to presentation has been identified 
as the most important risk factor for MRSA carriage,32 
but other factors, such as the presence of preexisting 
chronic disease, are also important.33 For this reason, we 
have subdivided apparently community-acquired cases 
into those with and without risk factors for MRSA 
acquisition. Only five of the 34 apparently community- 
acquired cases in our study occurred in patients with 
chronic diseases. Hence, we consider that most cases of 
nmMRSA in our study were truly community acquired. 
Community-acquired MRSA infections have 
previously been identified as a significant problem 
for the Pacific Islander community in eastern 
Australia,1,13-1s.29,30 and in Australia there is an 
increasing awareness of these infections in this ethnic 
group. Fourteen patients in our study (32%) were born 
in the south-western Pacific Islands or New Zealand, 
compared to 3% of the Ipswich population.16 Hence, 
there is a roughly lo-fold increased risk of nmMRSA 
infection in Pacific Islanders or New Zealanders in the 
Ipswich area compared to the general population. A 
similar rate of increased risk in Pacific Islanders and 
New Zealanders was noted in a study from Sydney, 
Australia.ls 
0 
March April May June July August September October November December January February March April May June 
2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2001 2001 2001 2001 2001 2001 
Months 
Figure 3. Incidence and types of 5. aureus isolated at lpswich Hospital microbiology laboratory. MSSA, methicillin-susceptible S. 
aureus; Gen R MRSA, gentamicin-resistant MRSA (predominantly nosocomially acquired strains); Gen S MRSA, gentamicin-susceptible 
MRSA (predominantly community-acquired strains). 
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Community-acquired MRSA infections have only 
relatively recently emerged in the Caucasian population 
in Australia.11J4J5 In our study, roughly half of the 
nmMRSA infections in Caucasians were due to the 
Pacific Island strain, and half were due to the emergence 
of the new strain that we have termed the R pulsotype. 
We note, however, that the proportion of nmMRSA in 
the Caucasian population rose from 45% in the first 6 
months of the study, to 80% in the last 6 months of the 
study. This was primarily due to the emergence of the R 
pulsotype strain, which has not previously been reported 
from Queensland,14,31 and which was predominantly 
community acquired. Unfortunately, we are unable to 
provide accurate figures on the incidence of nmMRSA 
prior to the year 2000, as these files are no longer 
available on our laboratory information system 
database. 
The rising incidence of community-acquired MRSA 
infections raises the question of whether to isolate or 
cohort these patients on admission to hospital, 
particularly if they have open skin lesions. Isolation or 
cohorting is a common practice in some Australian 
states, to prevent cross-transmission of nosocomial 
multiresistant strains of MRSA, and the question of 
whether to do the same for community-acquired strains 
has not been well addressed in the current literature. A 
nosocomial outbreak of infection due to cross- 
transmission of the community-acquired WA-MRSA 
strain has been reported, I1 but reports of nosocomial 
cross-transmission of community-acquired MRSA 
strains are much less frequent than those of the well- 
documented cross-transmission of nosocomial strains. In 
our study, there was no evidence of cross-transmission 
within the hospital of the Pacific Island strain, but there 
was a small cluster of apparent nosocomial cross- 
transmission of the R pulsotype strain. Since that time, 
it has been our practice to admit patients with open skin 
infections due to community MRSA into single rooms 
wherever possible, and we have not noted any further 
episodes of cross-transmission. 
In our study, 70% of patients with nmMRSA 
infection had superficial abscesses or boils. These 
infections were the predominant manifestation of 
community MRSA in other Australian studies.i4J5 
Because most infections occurred in a community 
setting and because the incidence of community MRSA 
in Australia is low, most patients were empirically 
treated with B-lactam antibiotics. Twenty-five of the 44 
patients in our study received only B-lactam antibiotics, 
which are not active against MRSA. Most of these 
patients were seen in the casualty department and were 
not reviewed after MRSA was cultured. Seventeen of 
the 25 patients who received non-active antibiotics had 
superficial abscesses or boils that were surgically incised 
and drained. It is likely that these patients were cured 
with surgery alone. The other eight patients who 
received non-active antibiotics had minor infections that 
did not require admission, such as cellulitis. 
The 19 patients in our study who received 
antibiotics that are active in vitro against MRSA mostly 
received parenteral vancomycin, or oral macrolides 
(clindamycin or erythromycin). The limited data 
available on the treatment of nmMRSA infections are 
difficult to interpret, because many infections respond to 
drainage alone, as illustrated by many of our cases. Most 
publications either extrapolate from non-p-lactam 
therapy of methicillin-susceptible S. aweus infection or 
consist of anecdotal reports.34 In Australia, treatment of 
nosocomial multiresistant strains of MRSA is with 
parenteral vancomycin or combination oral therapy, 
usually with rifampicin and fusidic acid (if strains are 
susceptible in vitro to these agents).34 Monotherapy 
with oral antibiotics for nosocomial multiresistant 
MRSA strains has been associated with the rapid 
emergence of resistance, with, for example, up to 70% of 
Australian strains of nosocomial MRSA now resistant to 
ciprofloxacin.l At present, there are few clinical trials to 
show whether non-multiresistant strains of MRSA can 
be treated with antibiotics that test sensitive in vitro, but 
that have not traditionally been used to treat MRSA 
infections, such as clindamycin. There are anecdotal 
reports of the efficacy of clindamycin, a bacteriostatic 
agent, for the treatment of mild-to-moderate infections 
caused by community-acquired MRSA,34,35 and it is an 
effective therapeutic agent in methicillin-susceptible ,S. 
aureus infections.36 In general, we would not recom- 
mend the use of clindamycin in erythromycin-resistant 
strains, as these strains may have inducible MLSn 
resistance to other macrolides such as clindamycin,29,37 
and failure of clindamycin therapy has been reported for 
such strains.37 We would also generally avoid bacterio- 
static agents such as clindamycin for serious infections, 
such as endocarditis or septicemia. 
There are also limited data available on the treat- 
ment of serious life-threatening nmMRSA infections.34 
All four patients in our study with serious life- 
threatening infections (Table 1) were cured with 
parenteral vancomycin, which is generally considered 
the gold standard therapeutic agent for MRSA 
infection. We caution, however, that the widespread 
empirical use of vancomycin may hasten the emergence 
of vancomycin resistance in staphylococci and other 
Gram-positive bacteria, such as enterococci.38 Hence, 
the empirical use of vancomycin for community- 
acquired staphylococcal infections should be avoided, 
unless the prevalence of community-acquired MRSA 
exceeds an acceptable threshold. We consider that the 
current rate of approximately 10% of all S. azdreus 
strains isolated at the Ipswich Hospital is too low to lead 
to a recommendation of a change from empirical p- 
lactam therapy of suspected staphylococcal infection to 
other non-B-lactam therapies, but we plan to 
periodically review these rates and antibiotic policies in 
the future. It should also be noted that preliminary data 
suggest that current rates of community MRSA in other 
parts of Australia are less than this figure,31 and, based 
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on our knowledge of these data, we would not advocate 
a change to the empirical therapy of staphylococcal 
infection in other parts of Australia at present. 
Thus, there is now evidence that community- 
acquired MRSA infection, relatively frequently 
observed in the Pacific Islander community of south- 
east Queensland, is a risk to the Caucasian community 
as well. Clinicians should be aware of the presence of 
this organism, and should consider taking microbio- 
logical specimens from patients with suspected 
staphylococcal infections who are not responding to 
empirical therapy with p-lactam antibiotics. 
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